San Jose, CA -- Tuesday, August 04, 2009 -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the U.S. launch of the BD FACSLink™ LIS (Laboratory Information System) interface solution designed to help clinical laboratories that use BD clinical flow cytometry instruments handle test orders more efficiently.
“As today’s clinical laboratories strive to improve productivity, the need to interface flow cytometry systems with their LIS is becoming increasingly important,” said Don Fourby, Director of Software Marketing, BD Biosciences. “Connecting to a LIS enables the direct transfer of data, which reduces errors caused during manual transcriptions.”
The BD FACSLink LIS interface solution is powered by Instrument Manager™ software from Data Innovations, Inc.., a leading middleware provider with significant experience in the clinical market. It enables laboratory professionals to create work lists containing downloaded LIS test orders for BD FACSCanto™, BD FACSCanto™ II and BD FACSCalibur™ flow cytometers, as well as the BD FACS™ Sample Prep Assistant II (SPA II). Users can also select and transfer reviewed results from the instrument software to the LIS with no manual entry.
Whether users have a single BD FACSCanto flow cytometry system or many clinical BD FACS™ systems, the BD FACSLink LIS interface solution allows them to configure and set up LIS connectivity with each BD flow cytometer in the laboratory. The software solution also includes a remote access capability that allows users to create a work list or transfer analyzed and reviewed results from any BD workstation in the laboratory.
“BD Biosciences is committed to offering comprehensive, innovative technologies and products that support research to better understand cell processes and disease,” said Fourby. “This commitment extends beyond our flow cytometry systems and reagents to integrated software solutions that improve overall lab workflow and productivity.”
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
